about
Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysisTreatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol.Phosphate and cardiovascular diseaseA randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney diseaseEffect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism?Calcium-deficiency assessment and biomarker identification by an integrated urinary metabonomics analysis.Vitamin D resistance in chronic kidney disease (CKD).Progression of glomerular and tubular disease in pediatrics.Vitamin D Binding Protein Is Not Involved in Vitamin D Deficiency in Patients with Chronic Kidney Disease.CYP2D6, GST-M1 and GST-T1 enzymes: expression in parathyroid gland and association with the parathyroid hormone concentration during early renal replacement therapy.The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysisApplication of total parathyroidectomy with auto-transplantation for uremia secondary hyperparathyroidism treatment.Association between ambient carbon monoxide and secondary hyperparathyroidism in nondiabetic patients undergoing peritoneal dialysisComparison of total parathyroidectomy without autotransplantation and without thymectomy versus total parathyroidectomy with autotransplantation and with thymectomy for secondary hyperparathyroidism: TOPAR PILOT-Trial.Geographic variation of parathyroidectomy in patients receiving hemodialysis: a retrospective cohort analysisThe OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidismImpaired vitamin D metabolism in CKDSerum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction.Activator protein 2alpha mediates parathyroid TGF-alpha self-induction in secondary hyperparathyroidism.Mineral metabolic abnormalities and mortality in dialysis patients.Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failureRisk factors associated with secondary hyperparathyroidism in patients with chronic kidney disease.Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study.Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism.Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortalityAllosteric modulation of the calcium-sensing receptor.Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease.Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis.Unplanned 30-Day Readmissions after Parathyroidectomy in Patients with Chronic Kidney Disease: A Nationwide Analysis.The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease.Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary carePharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan
P2860
Q27011288-734BFDB6-469D-4571-A2BE-E9B20DD7E6DCQ33506544-D4DB6BEB-0E04-4061-8B9C-17482EC83368Q33566596-26444612-AABD-44C5-AEAD-F3D0E15D7D74Q33821566-BBB13884-CE80-493A-88CA-8C0BC49088ADQ33917786-EFCAF4C2-87DC-40C6-8FFE-DBED2A0AAA62Q34366087-C1820A81-E110-42D8-98CC-35CFAE6953D1Q34640062-00D7AC9B-DD05-43AE-9CE3-2CB27C62D011Q35123615-DDB3416D-32CD-425B-9C09-1150F69F5FA0Q35234337-D6A0FF92-DD2F-4BB7-9B5E-49C44F3B75DAQ35614174-EB59B94A-8DAC-4532-BE33-77405886137CQ35825603-39729937-4243-4E38-93BA-E6020AA41455Q35826159-901B6DF0-36AB-4288-89D1-B5E8766F0A7FQ36046549-C1A0D75F-01D6-4A1B-9D10-02CB5614CF5EQ36079391-2F02D137-B96F-4200-9F5A-AB9985F33655Q36138126-B6C3CBBD-6EA3-4AFD-ACE2-B9214C4D891FQ36207167-7EE7A0FA-E44C-4DF9-B074-1667EB26E86BQ36666922-AC389210-6C9A-4FE0-82D4-AEF3E5220E58Q36668070-6C2730ED-8FF8-457B-8856-E8FD70D5BF57Q36880126-0A28CDC7-6A69-476D-A529-6E71B5E3B0B2Q36906034-583F3D07-5D1C-4FB7-8852-4B08FBF68EEEQ36994038-212C8C49-FAC8-480F-AB42-5D55556EAE5FQ37101624-ED40F697-2BDA-47BF-898F-F41F718D067DQ37108009-FAE0D218-3D66-462D-805F-B600981A4572Q37125654-39AF5126-3EFE-42B9-B1F2-540AF4141730Q37449576-843202C8-A67B-4A41-8878-4168E64EB83EQ37722852-10453483-183C-4BBD-88FE-7F0526C7654BQ40179229-BA4630FC-6404-49F0-BCD5-98EBA41208AAQ43233976-5DDF1FB2-2172-44BE-AF2C-8A8FF5FF711BQ47275858-2444C0FC-2960-41F3-B2B2-63ACA5F0B1B5Q49825343-096271D6-10F5-4642-864F-8D4284B1F198Q50101289-ADA9BDB6-A020-416E-B3DC-25306C8F7051Q55413395-476E336E-9B79-4D79-80FB-85E95F36EEE3Q58715560-81D718A4-B9BA-4E99-8F3D-003D71A72877Q58750935-355D4647-1A2B-402C-B443-504D20A9FE72
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Pathogenesis of secondary hyperparathyroidism.
@ast
Pathogenesis of secondary hyperparathyroidism.
@en
type
label
Pathogenesis of secondary hyperparathyroidism.
@ast
Pathogenesis of secondary hyperparathyroidism.
@en
prefLabel
Pathogenesis of secondary hyperparathyroidism.
@ast
Pathogenesis of secondary hyperparathyroidism.
@en
P2093
P1476
Pathogenesis of secondary hyperparathyroidism.
@en
P2093
P577
1999-12-01T00:00:00Z